It takes on average 10-12 years to get an experimental drug to market in the United States. For startups, it’s usually toward the longer end of the spectrum.
At the current 5.5 years you’ve waited, that’s not anywhere close to the national average. I’d expect this to be approved or rejected within the next 18 months so there still well under the average.
Perhaps the issue isn’t so much the length of time it’s taking but rather impatience from investors? I’m sure Dr. Missling with his 1 million shares or whatever has a more vested interest than any of us in seeing data results, unless you believe it’s an intentional delay to continue milking a salary?
Your frustration ought to be with the FDA. They’re the ones responsible for bottlenecks and drug approval holdups, but most people prefer well-tested drugs rather than quick approvals to satiate a few impatient investors.
5.5 years is a long time to wait. It seems that those who got in a year ago sub-$2 were the ones who timed this perfectly. You and I, not so much…
News 
Market Data 
Discover 
AI
